The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

England's National Health Services plans to offer Eli Lilly's weight-loss drugs to nearly a quarter million people as part of ...

Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

FDA announces Eli Lilly's Tirzepatide is no longer in shortage in the US. Impact on compounded GLP-1s & semaglutide supply.

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

"GMA" shares an exclusive look inside the lab of the maker of such drugs as Mounjaro and Zepbound to show what it's doing to ...